Disease selection, target identification and validation, lead finding and optimization, preclinical and clinical trials, and drug discovery and development are all extremely time-consuming and expensive processes . The number of novel molecular entities (NMEs) that the U.S. Food and Drug Administration (FDA) have authorized has clearly increased in recent years with the advent of in-silico technologies . Many drug ideas still fall short of becoming actual medications, though. The two main factors that contribute to therapeutic failure are ineffectiveness and safety , therefore chemical characteristics like absorption, distribution, metabolism, excretion, and toxicity (ADMET) are crucial at every stage of drug discovery and development. Finding effective compounds with improved ADMET characteristics is therefore important .